 | • レポートコード：B-MOR-040922 • 出版社/出版日：Mordor Intelligence / 2018年2月 • レポート形態：英文、PDF、116ページ • 納品方法：Eメール（受注後2営業日） • 産業分類：医療・バイオ |
| Single User（1名様用） | ￥629,000 (USD4,250) | ▷ お問い合わせ |
| Team User（7名様用） | ￥666,000 (USD4,500) | ▷ お問い合わせ |
| Corporate User | ￥1,295,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本資料は、急性骨髄性白血病の世界市場について調べ、急性骨髄性白血病の世界規模、市場動向、市場環境、治療法別（化学療法別、ホルモン療法、その他）分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、日本市場規模、中国市場規模、企業の競争環境、関連企業情報などをまとめた調査レポートです。 ・イントロダクション ・エグゼクティブサマリー ・急性骨髄性白血病の世界市場インサイト ・急性骨髄性白血病の世界市場環境 ・急性骨髄性白血病の世界市場動向 ・急性骨髄性白血病の世界市場規模 ・急性骨髄性白血病の世界市場規模：治療法別（化学療法別、ホルモン療法、その他） ・急性骨髄性白血病の世界市場：地域別市場規模・分析 ・急性骨髄性白血病の北米市場規模・予測 ・急性骨髄性白血病のアメリカ市場規模・予測 ・急性骨髄性白血病のヨーロッパ市場規模・予測 ・急性骨髄性白血病のアジア市場規模・予測 ・急性骨髄性白血病の日本市場規模・予測 ・急性骨髄性白血病の中国市場規模・予測 ・急性骨髄性白血病のインド市場規模・予測 ・急性骨髄性白血病の韓国市場規模・予測 ・関連企業情報・競争状況 |
The global Acute Myeloid Leukemia market is expected to register a CAGR of 14% during the forecast period, 2018 to 2023. North America dominates the market due to the higher awareness of the condition and the drugs that treat it, continued acceptance towards existing therapeutics
High Incidence and prevalence rate of Acute Myeloid Leukemia
Acute Myeloid Leukemia (AML) is very common in adults which accounts for 80 percent of cases. In the United States (U.S.) the cases of AML ranges from three to five cases per 100000 population. According to a Cancer statistics in 2015 there are 20830 new cases that are diagnosed and 10,000 are died from this disease. Increasing expenditure on healthcare. Increasing expenditure on healthcare according to new data from the centers on Medicare and Medicaid Services U.S. Spent $3.2 trillion on healthcare in 2015.
Additionally, increasing investment in Research and development (R&D) and advancement in pharmacology and molecular biology to promote drug development are also driving the Global Acute Myeloid Therapeutics Market.
Complications related to chemotherapy
Chemotherapy treats various types of cancer. But also causes side effects differently in different patients at different locations and thus highly depend on the type of cancer, location of the cancer, drugs and their dose and general health of the individual. Common side effects of chemotherapy headaches, muscle pain, stomach pain and pain from nerve damage that is burning and numbness.
Additionally, stringent regulatory guidelines of government in the different regions for these therapeutics is restraining the global acute myeloid leukemia therapeutics market.
North America to Dominate the Market
The Global Acute Myeloid Leukemia Therapeutics market is segmented into chemotherapy and by geography. The chemotherapy segment includes CALGB 8811 regimen, hyper – CVAD regimen, Oncaspar, linker regimen, nucleoside inhibitors, and others. Geographically the market has been segmented into North America, Europe, Asia-Pacific, the Middle East & Africa and South America.
North America is dominating the acute myeloid leukemia therapeutics market due to rising incidence of acute myeloid leukemia therapeutics, rise in the healthcare expenditure in that region, high investment in the development of the pipeline drugs and awareness among the people for the treatment of the acute myeloid leukemia therapeutics. Asia Pacific is expected to be the fastest growing region over the forecast period.
Key Developments in the Market
• June 2017: Genmab received US FDA approval for the Darzalex for the relapsed or refractory multiple myeloma.
Key Players: GENMAB A/S, GLAXOSMITHKLINE, BRISTOL MYER SQUIBB, NOVARTIS AG, ROCHE, CELEGENE CORPORATION AND EISAI CO LTD.
REASONS TO PURCHASE THIS REPORT
• Current and future Acute Myeloid Leukemia Market outlook in the developed and emerging markets
• Analyzing various perspectives of the market with the help of Porter’s five forces analysis
• The treatment type that is expected to dominate the market
• Regions that are expected to witness fastest growth during the forecast period
• Identify the latest developments, market shares and strategies employed by the major market players.
• 3 months analyst support along with the Market Estimate sheet in excel.
CUSTOMIZATION OF THE REPORT
• This report can be customized to meet your requirements. Please connect with our analyst, who will ensure you get a report that suits your needs.
レポート目次TABLE OF CONTENTS
1. INTRODUCTION
1.1 MARKET DEFINITION
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. KEY INFERENCES
5. MARKET OVERVIEW
5.1 CURRENT MARKET SCENARIO
5.2 PORTERS FIVE FORCES
5.2.1 BARGAINING POWER OF SUPPLIERS
5.2.2 BARGAINING POWER OF CONSUMERS
5.2.3 THREATS OF NEW ENTRANTS
5.2.4 THREAT OF SUBSTITUTE PRODUCT AND SERVICES
5.2.5 COMPETITIVE RIVALRY WITHIN THE INDUSTRY
6. DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES ANALYSIS (DROC)
6.1 MARKET DRIVERS
6.1.1 HIGH INCIDENCE AND PREVALENCE RATE OF ACUTE MYELOID LEUKEMIA
6.1.2 INCREASING INVESTMENT IN RESEARCH AND DEVELOPMENT (R&D)
6.1.3 ADVANCEMENT IN PHARMACOLOGY AND MOLECULAR BIOLOGY TO PROMOTE DRUG DEVELOPMENT
6.2 MAARKET RESTRAINT
6.2.1 COMPLICATIONS RELATED TO CHEMOTHERAPY
6.2.2 STRINGENT REGULATORY GUIDELINES OF GOVERNMENT
6.3 OPPORTUNITIES
6.4 KEY CHALLENGES
7. MARKET SEGMENTATION
7.1 BY CHEMOTHERAPY
7.1.1 CYTARABINE
7.1.2 ANTHRACYCLINE DRUGS
7.1.2.1 DAUNOMYCIN
7.1.2.2 IDARUBICIN
7.1.2.3 MITOXANTRONE
7.1.3 ALKYLATING AGENTS
7.1.4 ANTI-METABOLITES
7.1.5 TYROSINE KINASE INHIBITORS
7.1.5.1 DASATINIB (SPRYCEL)
7.1.5.2 IMATINIB (GLEEVEC)
7.1.6 HORMONAL THERAPY
7.1.7 OTHERS
7.2 SEGEMENTATION BY GEOGRAPHY
7.2.1 NORTH AMERICA
7.2.1.1 UNITED STATES
7.2.1.2 CANADA
7.2.1.3 MEXICO
7.2.2 EUROPE
7.2.2.1 FRANCE
7.2.2.2 GERMANY
7.2.2.3 UNITED KINGDOM
7.2.2.4 ITALY
7.2.2.5 SPAIN
7.2.2.6 REST OF EUROPE
7.2.3 ASIA-PACIFIC
7.2.3.1 CHINA
7.2.3.2 JAPAN
7.2.3.3 INDIA
7.2.3.4 AUSTRALIA & NEW ZEALAND
7.2.3.5 SOUTH KOREA
7.2.3.6 REST OF ASIA-PACIFIC
7.2.4 MIDDLE EAST AND AFRICA
7.2.4.1 GCC
7.2.4.2 SOUTH AFRICA
7.2.4.3 REST OF MIDDLE EAST AND AFRICA
7.2.5 SOUTH AMERICA
7.2.5.1 BRAZIL
7.2.5.2 ARGENTINA
7.2.5.3 REST OF SOUTH AMERICA
8. COMPETITIVE LANDSCAPE
8.1 MERGERS AND ACQUISITION ANALYSIS
8.2 AGREEMENTS, COLLABORATIONS & PARTNERSHIPS
8.3 NEW PRODUCTS LAUNCHES
9. COMPANY PROFILES
9.1 GENMAB A/S
9.2 GLAXOSMITHKLINE
9.3 BRISTOL MYER SQUIBB
9.4 NOVARTIS AG
9.5 ROCHE
9.6 CELEGENE CORPORATION
9.7 EISAI CO LTD
9.8 CLAVIS PHARMA
9.9 AMBIT BIOSCIENCE CORPORATION
10. FUTURE OUTLOOK OF THE MARKET